Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial - PubMed (original) (raw)
Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial
S J Horning et al. Cancer. 1985.
Abstract
Forty-nine patients with non-Hodgkin's lymphoma or Hodgkin's disease were entered into a multi-institutional phase II trial to evaluate the antitumor activity of human interferon alpha, prepared from buffy coats. Interferon alpha was administered intramuscularly in doses of 1 X 10(6) u, 3 X 10(6) u or 9 X 10(6) u daily for 30 days. Objective partial responses were seen in 3 of 18 patients with nodular lymphoma, all at the 9 X 10(6) u dose. Interferon alpha was not observed to be of therapeutic benefit in the other subtypes of non-Hodgkin's lymphoma or Hodgkin's disease. The major toxicities consisted of fatigue, fever, myalgias and weight loss. Serum interferon levels obtained 3 to 4 hours after injection varied widely, even among patients treated at the same dose level. Despite the relatively low doses of interferon used and the brief period of administration, this study extends the earlier observations of the antitumor effect of interferon in nodular lymphoma. These results are discussed in relation to the cumulative experience in human lymphoma using alpha interferons induced in human leukocytes and those produced in bacteria by recombinant DNA techniques.
Similar articles
- Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H, Gavigan M, O'Malley J, Thompson D, Dadey B, Nussbaum-Blumenson A, Snider C, Rudnick S, Ferraresi R, Norred S, et al. Ozer H, et al. J Biol Response Mod. 1983;2(6):499-515. J Biol Response Mod. 1983. PMID: 6607323 - Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon.
Foon KA, Sherwin SA, Abrams PG, Longo DL, Fer MF, Stevenson HC, Ochs JJ, Bottino GC, Schoenberger CS, Zeffren J, et al. Foon KA, et al. N Engl J Med. 1984 Nov 1;311(18):1148-52. doi: 10.1056/NEJM198411013111803. N Engl J Med. 1984. PMID: 6482933 - Phase I-II study of recombinant alpha-2 interferon against advanced leukemia and lymphoma in children.
Ochs J, Abromowitch M, Rudnick S, Murphy SB. Ochs J, et al. J Clin Oncol. 1986 Jun;4(6):883-7. doi: 10.1200/JCO.1986.4.6.883. J Clin Oncol. 1986. PMID: 3458876 - Current and future uses of recombinant interferon alpha in the treatment of low-grade non-Hodgkin's lymphoma.
Steis RG, Foon KA, Longo DL. Steis RG, et al. Cancer. 1987 Feb 1;59(3 Suppl):658-63. doi: 10.1002/1097-0142(19870201)59:3+<658::aid-cncr2820591315>3.0.co;2-q. Cancer. 1987. PMID: 10822466 Review.
Cited by
- Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.
Xuan C, Steward KK, Timmerman JM, Morrison SL. Xuan C, et al. Blood. 2010 Apr 8;115(14):2864-71. doi: 10.1182/blood-2009-10-250555. Epub 2010 Feb 4. Blood. 2010. PMID: 20139095 Free PMC article. - A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.
Rohatiner A, Radford J, Deakin D, Earl H, Love SB, Price O, Wilson A, Lister TA. Rohatiner A, et al. Br J Cancer. 2001 Jul 6;85(1):29-35. doi: 10.1054/bjoc.2001.1822. Br J Cancer. 2001. PMID: 11437398 Free PMC article. Clinical Trial. - Low-grade lymphomas: new entities and treatment concepts.
Hagemeister FB. Hagemeister FB. Med Oncol. 1995 Sep;12(3):131-42. doi: 10.1007/BF01571190. Med Oncol. 1995. PMID: 8852395 Review. - Interferon-alpha in malignant and viral diseases. A review.
Dorr RT. Dorr RT. Drugs. 1993 Feb;45(2):177-211. doi: 10.2165/00003495-199345020-00003. Drugs. 1993. PMID: 7681371 Review. - The management of follicular lymphoma.
Rohatiner AZ, Lister TA. Rohatiner AZ, et al. Drugs. 1994;47 Suppl 6:10-8. doi: 10.2165/00003495-199400476-00004. Drugs. 1994. PMID: 7525185 Review.
MeSH terms
Substances
LinkOut - more resources
Medical